title: Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
abstract: Colorectal cancer accounts for a significant proportion of cancer deaths worldwide. The need to develop more chemotherapeutic agents to combat this disease is critical. Cyclin dependent kinases (CDKs), along with its binding partner cyclins, serve to control the growth of cells through the cell cycle. A new class of drugs, termed CDK inhibitors, has been studied in preclinical and now clinical trials. These inhibitors are believed to act as an anti-cancer drug by blocking CDKs to block the uncontrolled cellular proliferation that is hallmark of cancers like colorectal cancer. CDK article provides overview of the emerging drug class of CDK inhibitors and provides a list of ones that are currently in clinical trials.
authors.affiliation: Archana Balakrishnan, Arpita Vyas, Kaivalya Deshpande, College of Human Medicine, Michigan State University, East Lansing, MI 48824, United States.
authors.forename: Archana
authors.initials: A
authors.lastname: Balakrishnan
authors.affiliation: Archana Balakrishnan, Arpita Vyas, Kaivalya Deshpande, College of Human Medicine, Michigan State University, East Lansing, MI 48824, United States.
authors.forename: Arpita
authors.initials: A
authors.lastname: Vyas
authors.affiliation: Archana Balakrishnan, Arpita Vyas, Kaivalya Deshpande, College of Human Medicine, Michigan State University, East Lansing, MI 48824, United States.
authors.forename: Kaivalya
authors.initials: K
authors.lastname: Deshpande
authors.affiliation: Archana Balakrishnan, Arpita Vyas, Kaivalya Deshpande, College of Human Medicine, Michigan State University, East Lansing, MI 48824, United States.
authors.forename: Dinesh
authors.initials: D
authors.lastname: Vyas
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D018844:Cyclin-Dependent Kinases
keywords: Colorectal cancer; Cyclin; Cyclin dependent kinase inhibitor